PL2083863T3 - Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej - Google Patents

Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej

Info

Publication number: PL2083863T3
Authority: PL; Poland
Prior art keywords: infants; tgf; antibodies; beta; risk
Prior art date: 2006-10-03

Application number

PL07867199T

Other languages

English (en)

Inventor

James B Streisand

Jesse D Roberts Jr

Original Assignee

Genzyme Corp

Massachusetts Gen Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-03

Filing date

2007-10-03

Publication date

2015-08-31

2007-10-03 Application filed by Genzyme Corp, Massachusetts Gen Hospital filed Critical Genzyme Corp

2015-08-31 Publication of PL2083863T3 publication Critical patent/PL2083863T3/pl

Links

206010006475 bronchopulmonary dysplasia Diseases 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Dispersion Chemistry (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL07867199T 2006-10-03 2007-10-03 Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej PL2083863T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US82793306P	2006-10-03	2006-10-03
PCT/US2007/021234 WO2008060371A1 (en)	2006-10-03	2007-10-03	USE OF TGF-β ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA
EP07867199.7A EP2083863B1 (en)	2006-10-03	2007-10-03	Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia

Publications (1)

Publication Number	Publication Date
PL2083863T3 true PL2083863T3 (pl)	2015-08-31

Family

ID=39217964

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL15154393T PL2918288T3 (pl)	2006-10-03	2007-10-03	Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej
PL07867199T PL2083863T3 (pl)	2006-10-03	2007-10-03	Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL15154393T PL2918288T3 (pl)	2006-10-03	2007-10-03	Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej

Country Status (10)

Country	Link
US (3)	US8642034B2 (pl)
EP (3)	EP3254696A1 (pl)
CN (2)	CN101553254A (pl)
DK (2)	DK2918288T3 (pl)
ES (2)	ES2538265T3 (pl)
HU (1)	HUE035575T2 (pl)
IL (2)	IL197797A (pl)
MX (1)	MX2009003518A (pl)
PL (2)	PL2918288T3 (pl)
WO (1)	WO2008060371A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140134181A1 (en) *	2010-11-05	2014-05-15	Kenneth E. Lipson	Treatment Method For Lung Remodeling Diseases
EP2912458B1 (en)	2012-10-24	2018-07-18	NYU Winthrop Hospital	Non-invasive biomarker to identify subjects at risk of preterm delivery
KR102258457B1 (ko)	2013-03-11	2021-05-31	젠자임 코포레이션	조작된 항-tgf-베타 항체 및 항원-결합 단편
CA2911514A1 (en)	2013-05-06	2014-11-13	Scholar Rock, Inc.	Compositions and methods for growth factor modulation
CN105658672A (zh)	2013-08-22	2016-06-08	阿塞勒隆制药公司	TGF-β受体II型变体及其用途
TWI726870B (zh)	2015-03-04	2021-05-11	美商健臻公司	具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh)	2015-03-04	2021-07-21	美商健臻公司	以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
CN116327952A (zh)	2015-08-04	2023-06-27	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
WO2017044302A1 (en) *	2015-09-09	2017-03-16	Rush University Medical Center	Compositions and methods for treating bone diseases
GB201610044D0 (en)	2016-06-08	2016-07-20	Ucb Biopharma Sprl	Antibodies
DK3628049T3 (da)	2017-05-04	2023-08-14	Acceleron Pharma Inc	Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
US20200264188A1 (en)	2017-09-13	2020-08-20	Progenity, Inc.	Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS606629A (ja)	1983-06-23	1985-01-14	Sumitomo Chem Co Ltd	ホルムアルデヒドの製造法
US5262319A (en)	1985-04-19	1993-11-16	Oncogene Science, Inc.	Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5705609A (en)	1988-06-28	1998-01-06	La Jolla Cancer Research Foundation	Decorin fragments inhibiting cell regulatory factors
FI906411A7 (fi)	1988-06-28	1990-12-27	La Jolla Cancer Res Foundation	Solujen lisääntymisen esto Decorinilla
US5654270A (en)	1988-06-28	1997-08-05	La Jolla Cancer Research Foundation	Use of fibromodulin to prevent or reduce dermal scarring
US5583103A (en)	1988-06-28	1996-12-10	La Jolla Cancer Research Foundation	Inhibition of transforming growth factor beta activity
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0494264B1 (en)	1989-09-29	1997-06-18	La Jolla Cancer Research Foundation	Inhibiting transforming growth factor to prevent accumulation of extracellular matrix
CA2068204C (en)	1989-11-22	2002-02-12	Arthur Levinson	Latency associated peptides and uses therefor
WO1991010727A1 (en)	1990-01-22	1991-07-25	La Jolla Cancer Research Foundation	Inhibitors of cell regulatory factors
FR2677038B1 (fr) *	1991-06-03	1994-08-12	Bel Fromageries	Additif alimentaire pour l'alimentation humaine et animale et aliments le contenant.
US6008011A (en)	1991-10-31	1999-12-28	Whitehead Institute For Biomedical Research	TGF-β type II receptor cDNAs
JP4124815B2 (ja)	1991-10-31	2008-07-23	ホワイトヘッドインスティチュートフォーバイオメディカルリサーチ	ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
CA2123418A1 (en)	1991-11-14	1993-05-27	Erkki I. Ruoslahti	Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
GB9205800D0 (en)	1992-03-17	1992-04-29	British Tech Group	Treatment of fibrotic disorders
US5821234A (en)	1992-09-10	1998-10-13	The Board Of Trustees Of The Leland Stanford Junior University	Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en)	1992-09-10	1999-02-09	The Board Of Trustees Of The Leland Stanford Junior University	Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en)	1992-10-26	1994-05-24	Kirin Brewery Company, Limited	Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
JPH08504763A (ja)	1992-10-29	1996-05-21	セルトリックスファーマシューティカルズ，インコーポレイテッド	治療薬としてのＴＧＦ−βレセプターフラグメントの使用
CA2147754A1 (en)	1992-10-30	1994-05-11	Michelle Letarte	Compositions and methods for modifying the regulatory activity of tgf- .beta.
US5830847A (en)	1992-10-30	1998-11-03	Hsc Research & Development Limited Partnership	Soluble TGF-β-binding endoglin polypeptides and homodimers
ATE211762T1 (de)	1993-04-30	2002-01-15	Biognostik Ges	Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
EP0737071A1 (en)	1993-06-15	1996-10-16	Il- Yang Pharm. Co., Ltd.	Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en)	1993-10-15	1995-05-04	La Jolla Cancer Research Foundation	Betaglycan polypeptides having tgf-beta binding activity
ATE208494T1 (de)	1994-05-04	2001-11-15	Mount Sinai Hospital Corp	Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung
US5772995A (en)	1994-07-18	1998-06-30	Sidney Kimmel Cancer Center	Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en)	1994-08-25	1996-02-26	Kenichi Matsunaga	Binding agent for growth factor
JPH08119984A (ja)	1994-08-31	1996-05-14	Nkk Corp	ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en)	1995-02-15	1998-10-20	The University Of Utah	Anti-transforming growth factor-β gene therapy
GB9601081D0 (en)	1995-10-06	1996-03-20	Cambridge Antibody Tech	Specific binding members for human transforming growth factor beta;materials and methods
CA2232682A1 (en)	1996-04-30	1997-11-06	Susan M. Richards	Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja)	1996-06-19	1998-03-10	Advanced Sukin Res Kenkyusho:Kk	細胞外マトリツクスの異常蓄積抑制剤
WO1998017304A1 (en)	1996-10-25	1998-04-30	Johnson & Johnson Medical, Inc.	Anti-fibrotic agent assay
TR199902878T2 (xx)	1997-04-18	2000-02-21	Biogen,Inc.	Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
US7779020B2 (en)	2002-03-01	2010-08-17	International Business Machines Corporation	Small-footprint applicative query interpreter method, system and program product
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
WO2000047102A2 (en) *	1999-02-11	2000-08-17	The General Hospital Corporation	COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING
US6492497B1 (en)	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
KR100425525B1 (ko)	2000-11-21	2004-03-30	재단법인서울대학교산학협력재단	조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트
AU2002239560B2 (en)	2000-11-28	2006-03-02	Premacure Ab	Determination of risk and treatment of complications of prematurity
DE60203263T2 (de)	2001-02-02	2006-02-09	Smithkline Beecham Corp.	Pyrazolderivate gegen tgf überexprimierung
GB0102668D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
GB0102673D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
GB0102672D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
US20040097502A1 (en)	2001-02-02	2004-05-20	Gellibert Francoise Jeanne	Pyrazoles as tgf inhibitors
GB0102665D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
ES2289116T3 (es)	2001-05-24	2008-02-01	Eli Lilly And Company	Nuevos derivados de pirrol como agentes farmaceuticos.
EP1478354A4 (en)	2002-01-22	2008-09-24	Genzyme Corp	USE OF TGF-BETA ANTAGONISTS IN THE TREATMENT OR PREVENTION OF CHRONIC RELEASE OF TRANSPLANT
AR039241A1 (es)	2002-04-04	2005-02-16	Biogen Inc	Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005530800A (ja)	2002-05-15	2005-10-13	スミスクライン・ビーチャム・コーポレイション	ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール
US20040038856A1 (en)	2002-05-17	2004-02-26	Sarvajit Chakravarty	Treatment of fibroproliferative disorders using TGF-beta inhibitors
CA2494367A1 (en)	2002-07-25	2004-02-05	Scios Inc.	Methods for improvement of lung function using tgf-.beta. inhibitors
GB0217786D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Compounds
UA80295C2 (en)	2002-09-06	2007-09-10	Biogen Inc	Pyrazolopyridines and using the same
UA80296C2 (en)	2002-09-06	2007-09-10	Biogen Inc	Imidazolopyridines and methods of making and using the same
AU2003272324A1 (en)	2002-09-10	2004-04-30	Scios Inc.	INHIBITORS OF TFGBeta
EP1543001B1 (en)	2002-09-17	2007-08-15	Eli Lilly And Company	Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
WO2004026302A1 (en)	2002-09-19	2004-04-01	Eli Lilly And Company	Methods of inhibiting tgf beta with substituted pyrazoles
JP2006524633A (ja)	2002-11-22	2006-11-02	サイオス・インコーポレーテツド	β−アドレナリン作動性経路における病理学的変化を打ち消すための方法
UA80571C2 (en)	2002-11-22	2007-10-10	Lilly Co Eli	Quinolinyl-pyrrolopyrazoles
AU2003291149A1 (en)	2002-11-22	2004-06-18	Scios, Inc.	USE OF TFG-Beta INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
WO2004048381A2 (en)	2002-11-22	2004-06-10	Eli Lilly And Company	Pyrazoloazepine compounds as pharmaceutical agents
AU2003290734A1 (en)	2002-11-27	2004-06-23	Eli Lilly And Company	Novel compounds as pharmaceutical agents
WO2004056352A1 (en)	2002-12-19	2004-07-08	Scios, Inc.	TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS
ATE553378T1 (de)	2003-02-06	2012-04-15	Hologic Inc	Screening und behandlungsverfahren zur vorbeugung von frühgeburten
CL2004000234A1 (es)	2003-02-12	2005-04-15	Biogen Idec Inc	Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
EP1608631A4 (en)	2003-03-28	2008-08-20	Scios Inc	BICYCLIC PYRIMIDININHIBITORS OF TGF BETA
EP1646655A2 (en) *	2003-07-09	2006-04-19	Eli Lilly And Company	Tgf-beta1 ligands
WO2005032481A2 (en)	2003-09-30	2005-04-14	Scios Inc.	Quinazoline derivatives as medicaments
KR20070007055A (ko)	2003-12-24	2007-01-12	사이오스 인코퍼레이티드	Ｔｇｆ-베타 억제제를 이용한 악성 신경교종의 치료법
EP1723146A1 (en)	2004-03-01	2006-11-22	Eli Lilly And Company	Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
CA2561686C (en)	2004-03-31	2014-12-02	Genentech, Inc.	Humanized anti-tgf-beta antibodies
DE102004019253A1 (de)	2004-04-16	2005-11-10	Codewrights Gmbh	Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
EP1789074A4 (en) *	2004-08-09	2009-08-12	Alios Biopharma Inc	PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
CA2578630A1 (en)	2004-08-31	2006-03-09	Wen-Cherng Lee	Pyrimidinylimidazoles as tgf-beta inhibitors
EP1786803A1 (en)	2004-08-31	2007-05-23	Biogen Idec MA, Inc.	Pyrimidinylpyrazoles as tgf-beta inhibitors
US7511056B2 (en)	2004-11-10	2009-03-31	Eli Lilly And Company	TGF-β inhibitors
PT3520815T (pt)	2005-02-08	2022-02-02	Genzyme Corp	Anticorpos contra tgfbeta

2007
- 2007-10-03 DK DK15154393.1T patent/DK2918288T3/da active
- 2007-10-03 US US12/444,059 patent/US8642034B2/en active Active
- 2007-10-03 CN CNA2007800447494A patent/CN101553254A/zh active Pending
- 2007-10-03 MX MX2009003518A patent/MX2009003518A/es active IP Right Grant
- 2007-10-03 ES ES07867199.7T patent/ES2538265T3/es active Active
- 2007-10-03 WO PCT/US2007/021234 patent/WO2008060371A1/en not_active Ceased
- 2007-10-03 CN CN201510002215.1A patent/CN104645328A/zh active Pending
- 2007-10-03 PL PL15154393T patent/PL2918288T3/pl unknown
- 2007-10-03 ES ES15154393.1T patent/ES2647472T3/es active Active
- 2007-10-03 DK DK07867199.7T patent/DK2083863T3/da active
- 2007-10-03 EP EP17181294.4A patent/EP3254696A1/en not_active Withdrawn
- 2007-10-03 HU HUE15154393A patent/HUE035575T2/en unknown
- 2007-10-03 EP EP07867199.7A patent/EP2083863B1/en not_active Not-in-force
- 2007-10-03 EP EP15154393.1A patent/EP2918288B1/en active Active
- 2007-10-03 PL PL07867199T patent/PL2083863T3/pl unknown
2009
- 2009-03-25 IL IL197797A patent/IL197797A/en active IP Right Grant
2013
- 2013-12-23 US US14/139,332 patent/US20140199399A1/en not_active Abandoned
2016
- 2016-11-28 US US15/362,392 patent/US20170233464A1/en not_active Abandoned
2017
- 2017-04-27 IL IL251994A patent/IL251994B/en active IP Right Grant

Also Published As

Publication number	Publication date
MX2009003518A (es)	2009-08-25
EP3254696A1 (en)	2017-12-13
EP2918288A1 (en)	2015-09-16
ES2538265T3 (es)	2015-06-18
IL197797A (en)	2017-05-29
IL251994A0 (en)	2017-06-29
EP2083863A1 (en)	2009-08-05
IL197797A0 (en)	2011-08-01
WO2008060371A8 (en)	2008-07-10
EP2083863B1 (en)	2015-03-18
CN104645328A (zh)	2015-05-27
PL2918288T3 (pl)	2018-02-28
EP2918288B1 (en)	2017-08-16
ES2647472T3 (es)	2017-12-21
HUE035575T2 (en)	2018-05-28
DK2083863T3 (da)	2015-06-22
US20140199399A1 (en)	2014-07-17
DK2918288T3 (da)	2017-11-27
US20170233464A1 (en)	2017-08-17
US8642034B2 (en)	2014-02-04
WO2008060371A1 (en)	2008-05-22
IL251994B (en)	2021-01-31
CN101553254A (zh)	2009-10-07
US20100008911A1 (en)	2010-01-14

Publication	Publication Date	Title
PL2083863T3 (pl)	2015-08-31	Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej
DK2069403T3 (da)	2014-07-28	Human-antistoffer med høj affinitet for human IL-4 receptor
ZA201000075B (en)	2010-09-29	Purin derivatives for use in the treatment of fab-related diseases
PL2391650T3 (pl)	2015-03-31	Sposoby leczenia dny
ZA201003131B (en)	2011-03-30	Anti-rsv g protein antibodies
IL228988A (en)	2017-02-28	Antibody preparations for the treatment of vaccine-related diseases
PL2068889T3 (pl)	2020-06-29	Anakinra do zastosowania do leczenia zespołu zarostowego zapalenia oskrzelików
PT2152290E (pt)	2014-09-03	Métodos para administrar anticorpos anti-il-5
ZA200808865B (en)	2009-10-28	Antibody composition and methods for treatment of neoplastic disease
DK2356151T3 (da)	2013-06-17	Human-antistoffer med høj affinitet for human IL-4 receptor
IL210802A0 (en)	2011-04-28	Purin derivatives for use in the treatment of fab-related diseases
HUE054495T2 (hu)	2021-09-28	Rák kezelésére szolgáló készítmény
PL1993577T3 (pl)	2014-07-31	Stosowanie nieulegających trawieniu sacharydów dla zapewnienia niemowlęciu najlepszego startu po narodzinach
BR112012004546A2 (pt)	2016-11-29	"terapêutica por proteínas ligantes dll4-ligantes"
ZA200905990B (en)	2010-05-26	Recombinant antibodies for treatment of respriratory syncytial virus infections
EP2084185A4 (en)	2010-11-17	HUMAN ANTIBODIES THAT NEUTRALIZE HUMAN METAPNEUMOVIRUS
EP2365947A4 (en)	2014-04-30	TREATMENT OF FLYBAG FOR USE IN CONCRETE
IL195152A (en)	2015-10-29	Compounds for use in treating diseases of cell culture
EP2200553A4 (en)	2014-06-25	LIGHT ABSORBENT TRANSPORT DEVICE
IL232011A0 (en)	2014-05-28	Antibodies to 7egfl and methods of using them
DK2839836T4 (da)	2024-08-26	Probiotika til anvendelse til reduktion af symptomer på luftvejssygdom
DE112009003128A5 (de)	2012-02-09	Aggregat zur nutzung alternativer energie
ZA200904068B (en)	2012-09-29	Anti-tsg101 antibodies and their uses for treatment of viral infections
EP2152894A4 (en)	2011-03-30	HUMAN BNP IMMUNE-SPECIFIC ANTIBODIES
IL219034A0 (en)	2012-06-28	Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer